Objective: Detection the presumptive prevalence of silent celiac disease in patients with type 1 diabetes mellitus with determination of which gender more likely to be affected.
Methods: One hundred twenty asymptomatic patients [75 male , 45 female] with type 1 diabetes mellitus with mean age ± SD of 11.25 ± 2.85 year where included in the study . All subjects were serologically screened for the presence of anti-tissue transglutaminase IgA antibodies (anti-tTG antibodies) by Enzyme-Linked Immunosorbent Assay (ELISA) & total IgA was also measured for all using radial immunodiffusion plate . Anti-tissue transglutaminase IgG was selectively done for patients who were expressing negative anti-tissue transglutaminase IgA with low total IgA levels & results were compared to that obtained from healthy 60 persons with mean age ± SD for them was 15.25 ± 3.85 year . Al - Kindy Col Med J 2012 ; Vol .8 No. (2) p: 132
Results : Fourteen out of one hundred twenty (11.66 % ) diabetic patients had expressed positivity to anti-tissue transglutaminase IgA compared to 1/60 ( 1.66 %) of non diabetic patients who had expressed such positivity , P value equals to 0.0221 & it is considered to be statistically significant. Three out of one hundred twenty (2.5 % ) diabetic patients had expressed total IgA deficiency whereas all of non diabetic patients were expressing total IgA within the normal range , P value equals to 0.55 & it is considered to be not statistically significant. All of three diabetic patients with total IgA deficiency were not showing positivity to anti-tissue transglutaminase IgG . Six mals & Eight female of those with type 1 diabetes mellitus had expressed positivity to anti-tissue transglutaminase IgA , P value equals to 0.1426 & it is considered to be not statistically significant .
Conclusion : There is an increased prevalence of IgA antitissue transglutaminase antibodies ( 11.66 % ) in children & adolescent with type 1 diabetes mellitus in comparison with control group.
(14)
(13)
Abstract Objectives: to determine efficiency and safety of three misoprostol regimens for 2nd trimester pregnancy termination in individuals with two or more cesarean section scars. Methods: a cross-sectional study included 100 pregnant ladies at 13th-26th weeks gestation with previous two cesarean sections (CSs) who were scheduled for pregnancy termination using misoprostol. Patients were conveniently assigned to 100µg/3h, 200µg/3h or 400 µg/3h regimens. Primary outcome was time to abortion, secondary outcomes were side effect and complications. Results: a significant association was found between number previous CSs and longer time to abortion (p=0.01). A highly significant association was identified between earlier gestatio
... Show More
(1)
(1)
Objectives: to evaluate patient knowledge with hemodialysis and to determine the effectiveness of Self-regulation Fluid Program on Patients with hemodialysis self-efficacy for fluid adherence in Al-Diwaniyah Teaching Hospital.
Methodology: A quasi-experimental design (two group design: pre-test and post-test) was used. This study was conducted in Al-Diwaniya Teaching Hospital for the period from (15th of October 2018 to 20th of May 2019) on a non-probability (purposive) sample consisting of (60 patients) treatment in hemodialysis units. A questionnaire was built as a data collection tool and consisted of four parts:
First part: Demographic characteristics of the pati
... Show More
(1)
(2)
The study objective was to conduct Pharmacoeconomics study (cost-effective analysis) between infliximab reference (Remicade) and its biosimilar (Remsima) in patients with rheumatoid arthritis (RA) in Iraqi hospitals.
This is a retrospective multicenter pharmacoeconomic analysis conducted at two large teaching governmental hospitals in Baghdad, Iraq which provided infliximab to patients with RA. Data were collected from patient’s medical records and face-to-face interviews with the patients from December 2021 to April 2022.
The study included 57 patients with rheumatoid arthritis (RA). The patients were categorized into two groups according to the type of infliximab they received over 30 weeks: 27 patients received
... Show More
(5)
(5)
(63)
(56)
(3)